Submitted Abstract
Due to demographic changes, socio-economical and population growth, the number of 8 M annual cancer casualties is expected to rise worldwide. We have developed a new, prototypic drug against one of the major cancer targets, named RAS. Our first aim is to assess the market opportunity of our drug through consultation also with bio-pharma companies. In the long-term, further improved drugs for personalized cancer therapies will be developed.